In accordance with the joint venture agreement between the société suzhou, the guinevere project, the sioux regional biomedicine company, the joint venture company shanghai biomedicine company ltd. And dr. Yao sheng, the transferring party (the company, the sioux state union, the kyoshi project and the sioux state league) conditionally agreed to (i) grant the joint venture a licence to license intellectual property for the research, development, manufacture, use and commercialization of licensed products; (ii) transfer of tangible assets to the joint venture; and (iii) transfer of ip interests to the joint venture. As the cost of the foregoing, the cost is approximately rmb 5. 3008 million, and the joint venture will issue the company an additional registered capital of rmb 250,000。
The licensed products are those independently developed by the joint venture on the basis of the relevant (one or more) antibody sequences generated during the development of the licensed technology, including: (a) multi-specific antibody products (trigents and above); (b) even-coated products (axc, i. E. Antibody x conjugate); and (c) derivative or material equivalent products. Physical assets are located in instruments, equipment and ancillary facilities in pre-clinical research and development laboratories of the transferring party. Ip interests are all technical results, experimental data and technical secrets related to the target of the target line or reasonably expected to be used in the development of the licensed product. The target line is the development of antibody technology and adc platform technology for the three products in the field of oncology treatment。
In addition, the joint venture intends to enter into a replenishment agreement with dr. Yao sheng and the angel wheel investor, whereby the joint venture will be conditionally able to agree to subscribe to the joint venture at a total cost of us$ 15 million for the additional capitalization of the joint venture in the amount of rmb 46. 87. 5 million. The purchase price for the joint venture's registered capital per rmb is approximately rmb 218. 87, higher than the rmb 212. 32 for the joint venture's registered capital per rmb。
When the financing came to the ground, the shares were 14. 55 per cent, yao shing 34. 91 per cent, and the rest were held by the founding team, the employee-owned platform and the angel investor。
The announcement states that the joint venture has greater research and development potential and that dr. Yao sein, mr. Deng lingquan and mr. Liu hongchuan are professionals in the field of biomedicine, with extensive experience in the fields of innovative medicine development, industrial transformation and biomedicine investment financing, with international scientific background, innovative drug development practices and industrial resource integration capabilities, cumulative participation and leadership in the development and marketing of innovative biopharmaceuticals. With the financial support of angel wheel investors, further research and development by joint venture companies of targeted intellectual property rights will facilitate companies ' access to the benefits of subsequent research and development, listing and commercialization of related medicines. The conclusion of joint venture agreements and the transactions to be carried out under them will enable companies to optimize overall resource allocation, maintain a focused r & d pipeline and efficient input, and take full advantage of existing company patents. This contribution does not involve the company's existing commercial product interests and does not have a significant adverse impact on the company's financial position and performance。
